New findings could drive medical advances in genetic disorders that cause infertility

March 10, 2016

Dr. Gruber and his colleagues used a mathematical model to determine the medical and cost effectiveness of colorectal cancer genetic screening based on a simple family history. The study determined that the average cost effectiveness ratio, a measure of expenditure per life year gained by genetic testing, would be $26,000, significantly less expensive than the often-quoted benchmark of $50,000. The study further suggested that risk-assessment should begin between the ages of 25 and 35, and that genetic testing would be appropriate for those individuals whose mutation risk is 5% or greater. The study estimated that approximately 1% of the U.S. population over the age of 25, or 2.0 million Americans, would meet this criteria resulting in a potential market of more than $6 billion dollars for Myriad's COLARIS test. 

AACR President-elect Judy Garber, M.D., M.P.H., Director of the Center for Cancer Genetics and Prevention at the Dana-Farber Cancer Institute, hosted a conference call discussing the results of the study. The call is currently available online at>

"This will affect a wide population by changing our thinking about risk for colon cancer," said Dr. Garber.  "It is a huge step forward in terms of bringing the benefits of cancer genetics to the broader population using tests that have, in the past, been considered too expensive."

SOURCE Myriad Genetics, Inc.